A 12-month, multicenter, randomized, comparative, open-label study to investigate efficacy and safety of reduced level of TACrolimus with equimolar MyforTIC (Enteric coated Mycophenolate Sodium) or Mycophenolate Mofetil in de novo renal transplant recipients.

Trial Profile

A 12-month, multicenter, randomized, comparative, open-label study to investigate efficacy and safety of reduced level of TACrolimus with equimolar MyforTIC (Enteric coated Mycophenolate Sodium) or Mycophenolate Mofetil in de novo renal transplant recipients.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil; Tacrolimus
  • Indications Transplant rejection
  • Focus Pharmacodynamics
  • Acronyms myTACTIC
  • Sponsors Novartis
  • Most Recent Events

    • 12 Feb 2014 Status changed to active, no longer recruiting according to Clinical Trials Registry - India.
    • 27 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top